Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) News
New Biotech Startup Looks to Take On Pfizer, Moderna
Fighting hidden coronavirus variants is like a whack-a-mole game and this company wants to try a new approach.
5 Top Stock Gainers for Wednesday: Michaels, Alcoa, Ovid Therapeutics
Michaels, Alcoa, Horizon Acquisition, KemPharm and Ovid Therapeutics are five top gainers for Wednesday.
Novavax Loss Widens, Revenue Jumps as COVID Vaccine Effort Progresses
Novavax's loss widened on a big jump in revenue, as the biotech's CEO said it's making 'significant strides' toward bringing a COVID-19 vaccine to market.
Sec. Alex Azar: Antibody Treatments, Vaccines 'Weeks' Away
Former FDA doc calls Azar's claim 'happy talk' as most experts expect a much longer time before widespread rollout of either a vaccine or effective treatment.
Blackstone Agrees to Buy Takeda Pharmaceutical Unit for $2.3 Billion
Takeda Consumer Healthcare is a leading provider of over-the-counter medicines in Japan.
FDA OKs Plasma Treatment for Ill Covid-19 Patients
Plasma treatment would use antibodies of those who recovered from Covid-19.
Novavax Plunges for a Second Day on Revenue Miss, Vaccine Uncertainty
Many experts remain uncertain about whether a vaccine from Novavax will be successful and beat the multiple other candidates to market.
5 Stock Gainers for Monday: Nikola, Silvercorp Metals, Trevena
Nikola, Silvercorp Metals, Renewable Energy Group, Trevena and Novavax are some of Monday's top gainers.
Gas Prices Fall Below $4 A Gallon For the First Time Since March Amid Global Crude Market Declines
Gas prices extended their run of declines to 52 days overnight, falling below $4 a gallon for the first time since early March.
Disney Stock Soars As Streaming Total Tops Netflix, Price Hikes Unveiled For Disney+ and Hulu
"We believe we have plenty of room on price value," Disney CEO Bob Chapek said of the group's streaming price hikes. "And we do not believe that there's going to be any meaningful on our churn as a result."